Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2, 2016. The document serves as a transaction notification regarding a specific insider transaction rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed relates to a specific share transaction:
- Transaction Price: £12.47 per Ordinary Share
- Transaction Volume: 216 Ordinary Shares
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882)
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an acquisition of shares by a Person Discharging Managerial Responsibilities (PDMR).
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a statutory notification of an option exercise under the Company's ShareSave Plan.
Key Facts for Investor Verification
- Insider Identity: Mr. S Dingemans, Chief Financial Officer.
- Transaction Nature: Acquisition of 216 Ordinary Shares on December 1, 2016, following the exercise of options granted on October 30, 2013.
- Exercise Price: The shares were acquired at the fixed option price of £12.47, not the prevailing market price.
- Reporting Limitation: This filing does not contain quarterly or annual financial performance data; investors should refer to Form 20-F for comprehensive financial results.